ADMA Biologics ADMA

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.09 (+0.53%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of ADMA Biologics (ADMA)
    ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $17.02

    • Market Cap

      $4.03 Billion

    • Price-Earnings Ratio

      58.69

    • Total Outstanding Shares

      236.39 Million Shares

    • Total Employees

      624

    • Dividend

      No dividend

    • IPO Date

      October 17, 2013

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      C/o adma biologics, inc., Ramsey, NJ, 07446

    • Homepage

      https://www.admabiologics.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$-66.27 Million
    Net Cash Flow From Financing Activities$-66.27 Million
    Net Cash Flow From Investing Activities, Continuing$-7.23 Million
    Net Cash Flow$12.55 Million
    Net Cash Flow From Operating Activities, Continuing$86.05 Million
    Net Cash Flow From Investing Activities$-7.23 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Diluted Earnings Per Share$0.27
    Operating Income/Loss$114.89 Million
    Gross Profit$187.31 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Benefits Costs and Expenses$23.00 Million
    Basic Average Shares$232.63 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$68.13 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$68.13 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Equity$231.89 Million
    Assets$390.62 Million
    Other Current Liabilities$28.87 Million
    Other Non-current Assets$18.25 Million
    Liabilities And Equity$390.62 Million
    Liabilities$158.73 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ADMA from trusted financial sources

      Related Companies

      Additional publicly traded companies similar to ADMA Biologics (ADMA)
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.